At age 62 years, she was diagnosed and operated for estrogen receptor positive breast cancer with postoperative therapy with tamoxifen, a selective estrogen receptor modulator drug chosen because of less risk of negative effects on bone than aromatase inhibitor treatment. This evidence concerns the gene CYP19A1 and breast carcinoma.